Diligence memo · auto-generated · as of July 2, 2026
Rx Redefined Inc.
Rx Redefined Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Rx Redefined Inc. operates in Pharmaceuticals, based in Arroyo Grande.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Rx Redefined Inc. has raised $36M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $21M on 2024-12-11.
Most recent recorded round closed around 2024-12-11.
Valuation (modeled)modeled
Provath models Rx Redefined Inc. at approximately $126M (range $45M–$207M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.97× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era. Within the normal band (97% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 19 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round stepped up 2.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 76% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 59% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.